ZEN-3694 is an oral bioavailable bromodomain end-of-domain inhibitor (BETi) that can cause downregulation of AR signaling in models of metastatic castration-resistant prostate cancer (mCRPC).

 

Brand: BCM

 

Target: Epigenetic Reader Domain

 

Signaling Pathways: Chromatin/Epigenetic

 

Boiling Point: 539.0±60.0 °C(Predicted)

 

pKa: 7.38±0.30(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water. 

 

Isomeric SMILES: CC1=C(C(=NO1)C)C2=CC3=C(N=C2)N=C(N3CC4=CC=CC=C4)NC  

 

InChIKey: VUFGOHIETLJZRG-UHFFFAOYSA-N  

 

InChI: InChI=1S/C19H19N5O/c1-12-17(13(2)25-23-12)15-9-16-18(21-10-15)22-19(20-3)24(16)11-14-7-5-4-6-8-14/h4-10H,11H2,1-3H3,(H,20,21,22)

 

Attribute
[Chem Name]	1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-methylimidazo[4,5-b]pyridin-2-amine
[Synonym]	ZEN-3694; ZEN3694; ZEN 3694
[CAS No.]	1643947-30-1
[Formula]	C19H19N5O
[Molecular]	333.39
[Form]	Solid Powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag